.jpg)
Mizuho Securities analyst Difei Yang reiterated a Buy rating on FibroGen (NASDAQ: FGEN) today. The company’s shares closed yesterday at $59.70, close to its 52-week high of $63.
Yang noted:
“We took a closer look at Fibrogen’s pipeline product Pamrevlumab, currently in development for the treatment of diseases associated with fibrosis. We are encouraged by recent positive data in two indications; idiopathic pulmonary fibrosis (IPF) and pancreatic cancer. We believe the data lends credibility to the compound’s mechanism of action and we also highlight superior data in IPF vs. standard of care products. We reiterate our Buy rating and raise our PT to $74.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 22.0% and a 55.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
FibroGen has an analyst consensus of Moderate Buy.
See today’s analyst top recommended stocks >>
The company has a one-year high of $63 and a one-year low of $29.50. Currently, FibroGen has an average volume of 442.9K.
Based on the recent corporate insider activity of 123 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FGEN in relation to earlier this year. Most recently, in April 2018, Pat Controneo, the SVP, Finance and CFO of FGEN bought 33,550 shares for a total of $97,295.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs. It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
